Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 91

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 91
---
 hamper our ability to raise additional capital. There is a limited market for our
securities. Accordingly, investors may therefore bear the economic risk of an investment in our securities for an indefinite period of
time.

Additional stock offerings in the future
may dilute your percentage ownership of our company.

Given our plans and expectations
that we may need additional capital and personnel, we may need to issue additional shares of common stock or securities convertible or
exercisable for shares of common stock, including convertible preferred stock, convertible notes, stock options or warrants. The issuance
of additional securities in the future will dilute the percentage ownership of then current stockholders.

Our internal control over financial reporting may not
meet the standards required by Section 404 of the Sarbanes-Oxley Act, and failure to achieve and maintain effective internal control
over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act, could have a material adverse effect on our business
and share price.

Our management is currently required to report on the effectiveness of our internal control over financial
reporting. However, as a smaller reporting company and a non-accelerated filer, our independent registered public accounting firm will
not be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404 for as long as
we are not deemed an “accelerated filer” or “large accelerated filer.” The rules governing the standards that
must be met for our management to assess our internal control over financial reporting are complex and require significant documentation,
testing and possible remediation.

In connection with
the implementation of the necessary procedures and practices related to internal control over financial reporting, we may identify deficiencies
or material weaknesses that we may not be able to remediate in time to meet the deadline imposed by the Sarbanes-Oxley Act for compliance
with the requirements of Section 404. In addition, we may encounter problems or delays in completing the implementation of any requested
improvements and receiving a favorable attestation in connection with the attestation provided by our independent registered public accounting
firm. Failure to achieve and maintain an effective internal control environment could have a material adverse effect on our business,
financial condition and results of operations and could limit our ability to report our financial results accurately and in a timely manner.

Anti-takeover provisions in our stockholder
rights plan could make a third-party acquisition of us difficult.

We have a stockholder rights
plan that may have the effect of discour